Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

Castration-resistant prostate cancer (CRPC) development is the foremost concern after treatment of patients with high risk with locally advanced or metastatic prostate cancer. Androgen receptor (AR) is the main driver of CRPC development, through its interaction with epigenetic modifier genes, placi...

Descripción completa

Detalles Bibliográficos
Autores principales: Orea, María J., Angulo, Javier C., González-Corpas, Ana, Echegaray, David, Marvá, Marcos, Lobo, María V. T., Colás, Begoña, Ropero, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820886/
https://www.ncbi.nlm.nih.gov/pubmed/36614243
http://dx.doi.org/10.3390/ijms24010803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820886/
https://www.ncbi.nlm.nih.gov/pubmed/36614243
http://dx.doi.org/10.3390/ijms24010803

Ejemplares similares